Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval.

Read more at globenewswire.com